Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Weakness, Fatigue Can Signal Underlying Rheumatologic Disease

Simon M. Helfgott, MD  |  Issue: April 2017  |  April 17, 2017

Bone is a rich storehouse of growth factors, including activin A, TGF-beta, IGF-I and BMP-2, that not only have activity in bone as a part of normal remodeling but can impact other organs, including muscle. It is possible that during hyperactive bone resorption, as occurs in metastatic cancer, bone might have a predominant role over muscle in bone–muscle cross-talk and become a source of osteokines that affect muscle function. This has been demonstrated in a murine model of metastatic breast cancer that described a reduction in the strength of paw grip in the absence of tumor involvement of these muscles.5 Likewise, factors released from muscle, such as IGF-I, FGF-2, myostatin and IL-6, may play a critical role in bone metabolism that could further augment the role of bone in muscle dysfunction.

Can Weakness Cause Illness?

Is it possible for weakness to mediate disease rather than serve as its unwanted end result? The answer to this intriguing question may be at the heart of the pathogenesis of osteoarthritis (OA) of the knee. A thoughtful review of this topic by some of our colleagues summarized the data demonstrating that muscle weakness may be a predictor of the onset of knee OA, but its role in the progression of OA is less clear.6 A few pilot exercise studies have suggested a benefit for some patients at risk for knee OA because it may delay its onset, but exercise has not been shown to impact established OA.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Aging Muscles—Fighting Back

Despite the mixed results for exercise in the management of knee OA, it remains a great alternative to the option of doing nothing. Aging begets the loss of muscle, sarcopenia and, if left unopposed, weakness becomes an inevitability. Fight back with exercise.

For encouragement, look to those aging athletes who continue to excel at their advanced ages: the 85-year-old sub-four-hour marathon runner or the 105-year-old cyclist who continues to pedal at an impressive 14 mph.7,8 Their secret to success is their continued devotion to training and exercise. But for those who are not interested in dripping sweat, there are a few intriguing options that may help one regain one’s strength.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

By combining one of humankind’s oldest technologies, textile processing in the form of weaving and knitting, with new advanced materials, such as electroactive polymers, a new form of textile actuator has been developed. These are mass-fabricated, wearable textiles that can scale up force through their design that allows for greater stretch and flexibility. Coupled with tiny electrodes, these wearable materials may eventually provide a power boost to weakened muscles that enables the wearer to perform tasks with greater ease.9

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:Diagnosisfatigueillnessinflammatory myositisLupusMyopathyOsteoarthritisoutcomepatient careRheumatic DiseaserheumatologistthyroidTreatmentweakness

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    Case Report: Tumor Treatment Unleashes Autoimmunity

    November 17, 2019

    Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) axes have revolutionized therapy and improved survival in advanced cancers. However, these immune system modulators also lead to immune-related adverse events (IRAEs).1,2 In clinical trials, IRAEs mainly involved the gastrointestinal tract, skin, endocrine glands, liver and lung,…

    Rehabilitation and Myositis

    January 1, 2008

    Physical therapy to manage inflammatory muscle disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences